BioSpace News Archive

Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros’ cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%.

BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and aging-related diseases, today announced that it has raised $90 million in an oversubscribed Series C financing

Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for RZ402, an orally available plasma kallikrein inhibitor, which is in development for the treatment of diabetic macular edema (DME)

Leading Clinical Experts Discuss Advancing Personalized Breast Cancer Screening and Detection with Newly Launched ProFound AI Risk Added Market Growth Opportunit y Presented by Pioneering AI Breast Cancer Risk Offering Webinar Taking Place on Monday, December 7 @ 11am ET

With families continuing to work and attend school in the midst of rising COVID outbreaks, screening for fever, a primary symptom of COVID-19, has never been more important.

NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the first human commercial use of its Evo Cortical Electrode at Mayo Clinic in Rochester, Minnesota .

Preclinical and clinical data on anti-BKV monoclonal antibody MAU868 highlights promise of ongoing clinical development program for transplant patients

Biovanta Lozenges and On-The-Go Throat Spray are scientifically proven safer and more effective than leading over-the-counter drugs and homeopathic remedies

Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Alnylam® Pharmaceuticals as a limited distribution partner for OXLUMO™ (lumasiran).

UroGen Pharma Announces Podium Presentation of Final Jelmyto ® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology Clinically Meaningful Response Underscores Potential for Jelmyto to Become New Standard of Care for Patients with Low-Grade Upper Tract Urothelial Cancer Of the 58% of Patients who Achieved a Complete Response, 12-Month Durability of Response Estimated at 81.8% by Kaplan-Meier Analysis